Backed by data from the phase 3 SatraGO trials, satralizumab has the potential to offer patients a convenient, at-home treatment option.

The expanded indication makes risankizumab the first IL-23 inhibitor available for pediatric patients weighing under 40kg with plaque psoriasis or psoriatic arthritis, supported by phase 3 OptIMMize ...

The total costs of dementia are anticipated to be $818 billion in 2026, driven by quality-of-life losses for persons with dementia and care partners, according ...

History of adenotonsillectomy is associated with increased odds of pediatric-onset multiple sclerosis (POMS), according to a study published online May 29 in Mu ...

It is increasingly recognized that galactose-deficient IgA in the glomerulus activates the alternative complement system and drives IgA nephropathy, including in the tubules and interstitium, leading ...

For ifosfamide, used to treat sarcomas, lymphomas and testicular cancers, some doctors are already meeting to decide who gets treated.

The letter focuses exclusively on manufacturing control strategies for the biological component and contract manufacturing facility deficiencies. The Food and Drug Administration (FDA) has issued a ...

The new presentation is expected to provide an additional self-administration option for patients with polycythemia vera.

DT120 ODT significantly improved MADRS scores at week 6 compared with placebo (-13.3 vs. -5.2; P .0001). Topline data were announced from a phase 3 trial evaluating DT120 (lysergide) orally ...

RelabotulinumtoxinA is a liquid neuromodulator designed to deliver rapid clinical improvement in glabellar and lateral canthal lines.

The FDA has approved an expanded indication for Zoryve (roflumilast) cream 0.3% to include plaque psoriasis in pediatric patients aged 2 years and older.

Shorter hospitalization and lower transfusion rates seen with pulsed Thulium:YAG laser enucleation versus open simple ...